Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Disability in progressive MS is associated with T2 lesion changes

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Cell-based therapeutic strategies for multiple sclerosis

    Research output: Contribution to journalReviewResearchpeer-review

  3. Defining active progressive multiple sclerosis

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Comorbidity in multiple sclerosis is associated with diagnostic delays and increased mortality

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Employment, disability pension and income for children with parental multiple sclerosis

    Research output: Contribution to journalJournal articleResearchpeer-review

  • Gavin Giovannoni
  • Stuart Cook
  • Kottil Rammohan
  • Peter Rieckmann
  • Per Soelberg Sørensen
  • Patrick Vermersch
  • Anthony Hamlett
  • Vissia Viglietta
  • Steven Greenberg
  • CLARITY study group
View graph of relations
On the basis of various clinical and MRI measurements, the phase 3 Cladribine Tablets Treating Multiple Sclerosis Orally (CLARITY) study in patients with relapsing-remitting multiple sclerosis (RRMS) showed that short-course oral treatment with cladribine at cumulative doses of 3·5 and 5·25 mg/kg over 96 weeks was more effective than placebo. Achieving sustained freedom from disease activity is becoming a viable treatment goal in RRMS; we therefore aimed to assess the effects of cladribine on this composite outcome measure by doing a post-hoc analysis of data from the CLARITY study.
Original languageEnglish
JournalLancet Neurology
Volume10
Issue number4
Pages (from-to)329-37
Number of pages9
ISSN1474-4422
DOIs
StatePublished - 2011

    Research areas

  • Cladribine, Disease-Free Survival, Humans, Immunosuppressive Agents, Multiple Sclerosis, Relapsing-Remitting, Odds Ratio, Randomized Controlled Trials as Topic, Treatment Outcome

ID: 33166945